News 13.04.2022 ZÜRICH, Switzerland, April 13, 2022 (GLOBE NEWSWIRE) -- CDR-Life Inc., a biotechnology company pioneering a new and differentiated class of highly tumor-specific immuno-oncology therapeutics based on its proprietary antibody-based MHC-targeting T cell engager technology, today announced the closing of a $76 million Series A financing led by Jeito Capital and...
News 24.03.2022 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 24, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced the publication of preclinical data from MP0317 in Cancer Immunology Research, a journal of the...
News 23.03.2022 Zurich-Schlieren, Switzerland, March 23rd, 2022. TOPADUR Pharma AG, a clinical-stage biopharmaceutical start-up company developing first-in-class drugs for aging diseases, today announced that the European Patent Office (EPO) granted a patent covering its lead investigational drug product, TOP-N53 used for the treatment of chronic wounds. The European patent covers composition of matter for...
News 16.03.2022 Financial highlights CHF 30.7 million cash & cash equivalents, trade and other receivables at December 31, 2021 Product sales increased more than 100% to CHF 8.3 million Received USD 6 million (CHF 5.5 million) milestone payments from Checkmate Pharmaceuticals Received USD 7 million (CHF 6.4 million) up front with USD...
News 16.03.2022 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 15, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built proteins known as DARPin therapeutics, today announced its corporate highlights and audited financial results for 2021. Research...